During this time, significant advances were made in the field, contributing to the understanding of the functional alterations promoted by the expanded ATXN2, the molecular pathogenesis of SCA2, the development of the disease manifestations, and the development of symptomatic and supportive treatments. This evidence concerns the gene ATXN2 and spinocerebellar ataxia type 2.